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ABSTRACT
Objective: Helicobacter pylori resistance toward commonly used antibiotics is increasing leading to the treatment failure; hence, our aim is to 
determine the antibiogram susceptibility pattern of H. pylori strains isolated from Guwahati, Assam (Northeast India) and also to test the efficacy of 
the Brassica capitata against the multi and dual drug-resistant strains of North and Northeast India.
Methods: Minimum inhibitory concentration of different antibiotics was determined by agar dilution method. Disc diffusion method was used to 
check the efficacy of B. capitata against clarithromycin (CLR), metronidazole (MTZ), and levofloxacin (LEV)-resistant H. pylori strains.
Results: All the H. pylori strains were 100% sensitive to CLR, tetracycline, amoxicillin, and furazolidone. 72.8% of the strains were sensitive toward 
MTZ and 54.5% were sensitive toward LEV. B. capitata showed good efficacy against the resistant strains of H. pylori of North and Northeast India.
Conclusion: Most of the H. pylori strains from Northeast India were sensitive toward the commonly used antibiotics for the treatment regime. B. capitata 
is effective against H. pylori infection, suggesting its potential as an alternative therapy, and opens the way for further studies on identification of novel 
antimicrobial targets of B. capitata.
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INTRODUCTION
Helicobacter pylori is a Gram-negative microaerophilic gastric 
pathogen causing various gastroduodenal (GI) diseases such as 
gastritis, peptic ulcer, mucosa-associated lymphoid tissue lymphoma, 
and gastric cancer. It is classified as Class I carcinogen by IARC in 
1994 [1]. Its infection is present in more than half of the population 
worldwide [1-5] and to almost 80% of the Indian population [6]. 
Indian population is an amazing combination of diverse races and 
cultures; thus, its inhabitants also differ in their genetic traits. Till 
date, it was believed that dietary factors are responsible for high 
prevalence of such GI diseases in the Northeast region of India because 
of its geographically, culturally, and ethnically divergent population 
[7]. H. pylori-associated various GI diseases can be cured by proper 
eradication therapy which includes proton-pump inhibitor-based 
triple therapy with multiple antibiotics. The commonly used antibiotics 
are clarithromycin (CLR), amoxicillin (AMX), metronidazole (MTZ), 
furazolidone (FZ), tetracycline (TET), and levofloxacin (LEV) [8,9]. Use 
of the antibacterial agents in general population for curing the various 
respiratory and anaerobic infections has resulted in the emergence 
of antibiotic-resistant strains of H. pylori which is the prime cause of 
treatment failure. Resistance to various antibiotics such as MTZ (10–
90%), CLR (0–15%), FZ (0-13%), TET (1–2%), and AMX (0–1%) has 
been shown to be variable and dissimilar in various regions within the 
countries [10-14]. The prevalence of dual resistance and multidrug 
resistance has increased significantly in many countries and has 
become a major obstacle in eradicating the H. pylori infection [15]. 
For these reasons, the natural products can be an alternative to the 
commonly used drugs for the eradication of H. pylori.
Nature is a rich source of numerous natural resources which can 
have the beneficial effects such as anti-inflammatory, antidiabetic, 
and antioxidative [16]. It was observed and confirmed that diet rich 
in vegetables and fruits reduced the risk of having several chronic 
disorders and immune diseases. Brassica capitata (cabbage) is 
considered to be one of the natural gifts that are herbaceous and leafy 
plant belonging to the family of Brassicaceae, having anti-inflammatory 
property and is generally used in cooking [17,18].
Against this background, the present study has been conducted (1) to 
study the antimicrobial susceptibility pattern of H. pylori strains from 
Northeast India and (2) to evaluate the efficacy of B. capitata as an 
antimicrobial agent against the multi and dual drug-resistant strains of 
H. pylori isolates from North and Northeast India.
METHODS
Patients and specimens
A total of 98 biopsies were collected from the patients having an average 
age of 42.6 years and M:F ratio of 1:0.46 visiting Gauhati Medical 
College, Guwahati, Assam, with clinical symptoms of gastrointestinal 
disorders and underwent endoscopy. Samples were collected as per the 
inclusion and exclusion criterion.
An inclusion criterion includes
Patients aged >18 years with symptoms of duodenal or gastric ulcer/
gastritis/gastric adenocarcinoma/non-ulcer dyspepsia and no 
antimicrobial therapy to eradicate H. pylori infection.
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Exclusion criteria included
Previous gastric surgery, any use of bismuth, antimicrobial agents, 
H2 receptor antagonists, proton-pump inhibitors within 4 weeks 
before endoscopic examination, or any of several concomitant medical 
illnesses including cardiac, respiratory, renal, and liver diseases. The 
study was approved by the institutional ethical committee. All the 
patients who were enrolled in the study were not exposed to any prior 
antibiotics for H. pylori infection for the previous 2 weeks.
Isolation and identification of H. pylori
Two biopsies were collected from each patient with various GI 
symptoms, one for rapid urease test and other collected in transport 
media (Brucella broth + glycerol) were stored in −80°C deep freezer 
until transportation to Amity University, Noida, for culture. The biopsy 
samples were transported to Molecular Bacteriology Laboratory 
at Amity Institute of Biotechnology, Noida, in dry ice. The detail 
demographic performa of each patient was filled. The biopsies which 
were in transport media were used for the isolation of H. pylori on 
brain heart infusion agar media (BHIA) Becton Dickinson, Sparks, MD, 
USA, supplemented with 5% horse serum; 0.4% IsovitaleX (Becton 
Dickinson, Sparks, MD, USA), amphotericin B (8 μg/ml), trimethoprim 
(5 μg/ml), and vancomycin (6 μg/ml) and were allowed to incubate 
at 37°C for 3–6 days under microaerophilic condition (5% O2; 10% 
CO2; 85% N2) (double gas incubator, Heracell 150i). Identification of 
the H. pylori was on the basis of colony morphology, Gram staining, 
and observing the positive results of urease, oxidase, and catalase 
tests. For further use in future, the H. pylori suspension was stored in 
glycerol stock containing BHI broth and 20% glycerol and were stored 
at −80°C.
DNA extraction and polymerase chain reaction (PCR) amplification 
for the confirmation of the H. pylori
The bacteria were harvested by colony morphology, and the DNA was 
extracted by cetyltrimethylammonium bromide method [19] using 24 
h grown confluent lawn of bacterial culture on BHI agar (BHIA, Difco 
Laboratories) plates.
For molecular confirmation of H. pylori colonies, the 
urease gene was amplified using the primers sequence of 
UreBF5’-CGTCCGGCAATAGCTGCCATAGT3’ and UreBR5’-
GTAGGTCCTGCTACTGAAGCCTTA3’which gave an amplicon size 
of 480 bp [20]. The PCR was performed in a final volume of 20 µl 
containing 10X PCR buffer, 500 nM of each primer, 2 mM MgCl2, 200 µM 
each deoxyribonucleotide triphosphate, 1.5 U Taq DNA polymerase, and 
10 ng of DNA sample. PCR was performed in a thermocycler (Eppendorf, 
Germany) under the following condition; initial denaturation for 2 min 
at 96oC was followed by 30 cycles of 94°C for 30 s, 55°C for 30 s, and 
72°C for 40 s. After the final extension of 72°C for 10 min, the PCR 
products were examined by 1% agarose gel according to the standard 
procedure. H. pylori strain 26695 was used as a control strain.
Antibiotic susceptibility testing
The minimum inhibitory concentrations (MICs) for MTZ, FZ, AMX, 
TET, LEV (Sigma, St Louis, MO, USA), and CLR (Abbott Laboratories, 
Abbott Park, IL, USA) were determined by agar dilution method as per 
European Committee on Antimicrobial Susceptibility Testing (EUCAST) 
guidelines [21]. The positive isolates were considered to be resistant 
if the MIC was >8 μg/ml for MTZ, >0.12 μg/ml for AMX, >1 μg/ml for 
TET, >0.5 μg/ml for CLR, >2μg/ml for FZ, and >1 μg/ml for LEV [21]. 
For antibiogram profiling, 2-fold serial dilutions of antibiotics were 
used: MTZ 0.2–64μg/ml; FZ 0.2–2 μg/ml; AMX 0.12–2 μg/ml; TET 1–4 
μg/ml; CLR 0.125–2 μg/ml; and LEV 0.2–2 μg/ml. H. pylori suspensions 
were prepared equivalent to McFarland 2 (1×108 CFU/ml). 3 µl was 
delivered as a spot on BHIA plates containing different concentrations 
of antibiotics [22]. Antibiotics free BHIA plates were used as control. 
All the plates were further incubated under microaerophilic condition 
at 37°C for 72 h or longer until a visible inhibition ellipse was seen, 
and the results were interpreted as per EUCAST guidelines [21].
Collection of samples of B. capitate
B. capitata was collected from the local Indian market and was further 
authenticated at the Botany Department of Amity University. The leaves 
were washed properly and dried in room temperature for 5–10 days. 
These dried leaves were then grinded into powdered and extracted 
using methanol, n-hexane, and chloroform.
Preparation of the extract of B. capitata
The extract was prepared in methanol, n-hexane, and chloroform. 
To prepare the extract about 2 g of dried powdered plant sample 
was extracted with 30 ml of methanol, n-hexane, and chloroform 
consecutively for 72h under constant stirring. The extracts were 
filtered and collected separately, and 30 ml of respective solvent was 
added to it. The extracts were again filtered and collected after 72 h. 
The filtered extracts were dried under pressure and suspended in the 
solvent.
Anti-H. pylori assay of B. capitate by disc diffusion assay
The dual drug-resistant strains of H. pylori from Northeast India and 
multidrug-resistant strains from North India (from our previous study) 
were included to test the efficacy of n-hexane, methanolic, and chloroform 
extract of B. capitata. The bacterial colonies were taken directly from 
the BHIA plate and were suspended in 5 mL of sterile 0.85% phosphate 
buffer saline (PBS). The turbidity of the initial suspension was adjusted by 
comparing with McFarland’s standard number 2 (3 μl of which contains 
about 1×108 colony-forming units (CFUs)/ml) [23]. Sterile Whatman filter 
paper disks of 6 mm in diameter were loaded with different concentration 
of n-hexane, methanol, and chloroform extracts of B. capitata and placed 
on the inoculated plates with 3×109 CFU of H. pylori. The plates were kept 
under observation for 2 days at 37°C under microaerophilic conditions 
(5% O2, 10% CO2, and 85% N2). All experiments were performed in 
triplicates. Pure n-hexane, methanol, and chloroform were used as a 
negative control and AMX was used as positive control.
Statistical analysis
Differences between groups were statistically evaluated using the 
Chi-square test. Differences were considered significant at the 5% 
probability level. Statistical analysis was performed using SPSS ver.20 
software.
RESULTS
Isolation of H. pylori
A total of 98 biopsies were collected from the patients within the age 
group of 18–80 years who were suffering from various GI diseases 
visiting Gauhati Medical College, Guwahati, Assam. Among the 98 
biopsies which were transported to Amity University, Noida; in 
transport media, H. pylori was successfully isolated from 11 biopsy 
sample by culture method under microaerophilic condition. All the 
positive isolates were within the age of 18–80 years, with M/F ratio of 
1:0.46.The clinical diagnosis of all the isolates was antral erosion (n=3), 
antral ulcer (n=1), conjunctive dystrophy (n=1), duodenal ulcer (n=1), 
and gastritis (n=5).
Identification of the H. pylori
Rapid urease test (RUT)
The detection of the H. Pylori was done with RUT. H. pylori is urease 
positive and gives a pink color to the RUT solution (5% urea + 2% 
phenol red and PH 6.6–6.8) indicating the presence of H. pylori.
PCR detection for the confirmation of the H. pylori strain
The DNA of all the 11 isolates was amplified for urease gene using UreBF 
and UreBR primers. Analysis was done on 1% agarose gel confirming 
the presence of H. pylori (Fig. 1).
Antimicrobial susceptibility of the antibiotics
Agar dilution method was used for determining the MIC of all the 
antibiotics. Resistance toward MTZ was found in three isolates; MIC 
>32 µg/ml (n=1), MIC >16 µg/ml (n=1), and MIC >8 µg/ml (n=1).
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Resistance to LEV founded in 4/11 isolates (MIC >1 µg/ml). Of four-
resistant strains, three showed dual resistances to MTZ and LEV. All the 
(11/11) strains were 100% sensitive toward CLR, TET, AMX, and FZ.
Distribution of antibiotics as per the clinical information
The distribution of MTZ and LEV resistance according to the age, gender, 
and disease outcome is discussed in Table 1. As per the association of 
MTZ and LEV within gender, there was no significant association found.
However, the prevalence of MTZ and LEV resistance was observed more 
in the patients with the age group of 41–60 years than in the patients 
with age ranging from 18 to 40 and 61 to 80 years. The MTZ and LEV 
resistance was seen to be higher in the patients suffering from gastritis, 
but the association was not significant (Table 1).
All the 11/11 (100%) H. pylori strains were sensitive toward CLR, 
TET, AMX, and FZ, and the significant association was found with the 
gender (p>0.04) and the disease diagnosis (p≥0.004), but no significant 
association was found with patient’s age (p>0.3) (Fig. 2).
Effect of B. capitata against the resistant H. pylori strains
Two clinical isolates, one from North and other one from Northeast 
India, were included in the study. Of the two strains, one strain isolated 
from North Indian patient was multidrug resistant showing resistance 
toward MTZ, CLR, and LEV and the other from Northeast India was dual 
drug resistant showing resistance toward MTZ and LEV.
Different concentration of n-hexane, methanol, and chloroform extract 
was loaded on the disc and was air dried. 100 ul of the H. pylori strains 
dissolved in PBS having McFarland 2 (3×109 CFU/ml) was spread on 
the BHI plate. The disc loaded with the extracts was placed upside down 
on the H. pylori plates. After 72 h of incubation under microaerophilic 
condition, we found that the n-hexane, methanolic, and chloroform 
extract of B. capitata showed anti-H. pylori activity on both dual and 
multidrug-resistant strains (Table 2). The MIC for multidrug-resistant 
strain of North India was 100 µg for n-hexane, 20 µg for methanol, and 
10 µg for chloroform extracts. The diameter of zone of inhibition was 
found to be 8 mm, 6 mm for n-hexane, 7 mm for methanol, and 6 mm 
and 8 mm for chloroform extracts of B. capitata, respectively, for North 
and Northeast strains.
The MIC and the diameter of the zone of inhibition for dual drug-
resistant strain of Northeast India and multidrug-resistant strains 
of North India were similar when tested against various extracts of 
B. capitata (Fig. 3).
DISCUSSION
H. pylori infection causes several GI diseases in both developing 
and industrialized country and has direct impact on health-care 
system worldwide [24]. Eradication of H. pylori with a proton-pump 
inhibitor-based triple therapy is presently used to treat H. pylori 
infection [21]. Although it has a success rate of 80–90%, problems 
such as treatment failure and contraindications for some patients are 
common. Furthermore, rapidly emerging drug resistance in H. pylori 
strains during treatment with various antibiotics is a major obstacle for 
successful eradication therapies [1]. Due to the prevalence of antibiotic-
resistant H. pylori strains, there is an increasing search for safe and 
effective non-antibiotic compounds that inhibit H. pylori growth. In 
the Indian traditional medical system, a number of plants and plant 
products are known to possess potent medicinal properties, suggesting 
their usefulness in treatment.
Antibiotics, namely MTZ, CLR, and TET are the major drugs used for 
the treatment of several different types of infections including the 
H. pylori infection [25] which could be the reason for the high level of 
antibiotic resistance from mainly MTZ in many parts of India. Northern 
India such as Delhi and Chandigarh has reported a lower prevalence 
of resistant strains, i.e. 37.5% and 38.2%, respectively [26]. Eastern 
India observes high MTZ resistance with 85% [27] along with South 
India which includes Hyderabad and Chennai having 100% and 88.2%, 
respectively [28]. The MTZ resistance of H. pylori may be because of the 
extensive use of this inexpensive antibiotic for the treatment of parasitic, 
genital, and dental infections, especially in developing countries [29]. 
Fig. 1: DNA amplification of urease gene of 480 bp for the 
confirmation of Helicobacter pylori strains. Lane1- positive 
control, 26695;Lane 2-6 - H. pylori clinical isolates from Lane 
7 - negative control, and Lane M - Marker (100 bp)
Table 1: Correlation between MTZ and LEV susceptibility of  
H. pylori isolates with gender, age, and disease diagnosis
Clinical information MTZ (R) p LEV (R) p
Gender
Male (n=9) 3 (27%) 0.4 4 (36%) 0.36
Female (n=2) 0 (0%) 0 (0%)
Age
18–40 (n=6) 1 (9%) 0.4 1 (9%) 2.9
41–60 (n=3) 2 (18.1%) 3 (27%)
61–80 (n=2) 0 (0%) 0 (0%)
Disease diagnosis




0 (0%) 0 (0%)
Duodenal ulcer (n=1) 0 (0%) 0 (0%)
MTZ: Metronidazole, LEV: Levofloxacin, H. pylori: Helicobacter pylori
Table 2: Antimicrobial activity of n-hexane, methanolic, and chloroform extract of B. capitata against the dual and multidrug-resistant 
strains of North Indian (strain1) and Northeast India (strain 2)
Strain nos. MIC for MTZ, CLR, LEV  
(agar dilution method)
n-hexane extract of  
B. capitate (disc diffusion assay)
Methanolic extract of  
B. capitata (disc diffusion assay)
Chloroform extract of  
B. capitata (disc diffusion assay)
Amount  
(in µg)








Zone of inhibition  
(in mm)
Strain 1 MTZ=64 µg/ml
CLR=4 µg/ml
LEV=2 µg/ml
100 8 20 7 10 6
Strain 2 MTZ=32 µg/ml
LEV=1 µg/ml
100 6 20 7 10 8
B. capitata: Brassica capitata, MIC: Minimum inhibitory concentration, MTZ: Metronidazole, LEV: Levofloxacin, CLR: Clarithromycin
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Studies comprehend that the resistance is due to inactivation of gene 
rdxA and frx gene [30,31].
Another drug of choice for the treatment is CLR that is commonly used 
in the triple therapy for the eradication of H. pylori having an efficacy 
of 90% [32]. The level of resistance for CLR varies in India, namely 
Lucknow (82%), Mumbai (91%), Hyderabad (96%) [28], Kolkata 
(0%) [30], Gujarat (58.8%) [33], and Delhi (11.8%) [34]. Studies have 
shown that the CLR resistance is due to the mutation in the 23S rRNA 
gene at 2142 (A–G), 2143 (A–G), and 2182 (T–C) positions [34].
LEV can also be an option as a drug for the eradication of H.pylori as 
has been reported in many countries. According to the recommended 
guidelines, if the LEV resistance in the susceptibility test of H. pylori is 
over 20%, then the antibiotic is not considered as a good option. Its 
resistance rate in Gujarat is 13.8% [33] and in North India is 73.2% [35].
Our study reports on the antibiotic sensitivity pattern toward AMX, 
TET, CLR, and FZ of all the 11 Northeast strains isolated from Guwahati, 
Assam. We found that all the 11 strains were sensitive toward the AMX, 
TET, CLR, MTZ, LEV and FZ. It has been observed that 27% of the H. 
pylori strains showed resistance toward MTZ, 36.3% of the strains 
toward LEV and rest 27% toward both MTZ and LEV.
Due to increase use of antibiotics over the last two decades, H. pylori 
has acquired the antibiotic resistance which is one of the main causes 
of treatment failure. De et al. have mentioned the anti-H. pylori effect of 
curcumin and their use in the treatment of the H. pylori infection [36]. 
In our previous study, we have reported the efficacy of Emblica 
officinalis [37], Paedra foetida [38], and Parmelia perlata [39] against 
the drug-resistant H. pylori strains. B. capitata which is leafy vegetable 
and is used in cooking with the nutritive value being rich in calcium 
and protein, and Vitamin C is utilized for healing process [40,41]. This 
prompted us to explore its antimicrobial potential against multi and 
dual drug-resistant strains of North and Northeast India. The n-hexane, 
methanolic, and chloroform extract of B. capitata were tested by disc 
diffusion method for its efficacy against H. pylori. Zone of inhibition 
with the n-hexane extract for North Indian and Northeast strains at 
MIC of 100 µg was 8 mm and 6 mm, respectively. The methanol extract 
showed 7 mm zone for both the strains at MIC of 20 µg and chloroform 
extract showed the best effect at the MIC of 10 µg with 6 mm of zone 
of inhibition for North Indian strain and 8 mm zone of inhibition for 
Northeast strains.
Overall, this study provides novel insights into the therapeutic potential 
of B. capitata against H. pylori infections, although further studies are 
required to extrapolate its effect on humans.
CONCLUSION
Our study highlights the potential antibacterial activity of B. capitata 
against H. pylori in vitro irrespective of the genetic makeup of the 
strains. However, its MIC is relatively high which may be due to the poor 
bioavailability of B. capitata extracts. Furthermore, our study for the 
1st time in India studied the Northeast Indian strains which were found 
to be sensitive to most of the antibiotics used for the treatment regime, 
whereas other parts of India reported high multidrug resistance [29].
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